DURHAM, NC - Treatment for full-term babies born with hypoxic-ischemic– brain damage due to blood and oxygen deprivation injuries is currently limited to therapeutic cooling to improve outcomes. There is no treatment for pre-term babies; however, a new study appearing in the latest issue of STEM CELLS Translational Medicine may lead to therapies that repair damage from hypoxia-ischemia.
You are here
Press Releases from AlphaMed Press
Durham, NC – A new study in STEM CELLS Translational Medicine offers people with genetic hearing loss the promise of a new therapy that just might outperform artificial cochlear implants.
Implants currently are the most effective way to treat sensorineural hearing loss, a type of hereditary hearing loss caused by genetic mutations in the hair cells — the sensory receptors of the auditory system, found in the inner ear (the cochlea). A cochlear implant helps transfer sound to the patient’s hearing nerves and enables them to hear. But many researchers believe that stem cells could offer a more comprehensive and better fix for this problem.
Durham, NC – A study recently published in STEM CELLS Translational Medicine points the way to a new, potentially restorative treatment for age-related or type II osteoporosis. When a single dose of a certain type of stem cell, called mesenchymal stromal cells (MSCs), was injected into mice with the disease, long-term bone engraftment and quality bone growth resulted. As an added benefit, the cells protected existing bone from damage.
Durham, NC – A new type of engineered stem cell could transform how Alzheimer's disease (AD) is treated and perhaps even stop the disease in its tracks. In a study recently published in STEM CELLS Translational Medicine, a team of University of Michigan researchers describe how they revved up the levels of a protein called IGF-I in a line of neuronal stem cells (NSCs), which resulted in the NSCs producing brain cells that were both resistant to AD and capable of restoring AD-ravaged cells to normal.
Durham, NC – A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method for turning fibroblasts — the most common cells in connective tissue — into cardiac progenitor cells (CPCs). The results could lead to a much-needed new source of cells for regenerating the heart. Equally exciting is that the technology also converts the fibroblasts directly to CPCs, skipping an in-between and significantly speeding up the process.
DURHAM, N.C., June 23, 2015 /PRNewswire-iReach/ -- To date, the only definitive treatment for heart failure – an organ transplant – is hampered by both the limited number of organ donors and the potential for the patient's body to reject the new heart. However, findings of a study published in STEM CELLS Translational Medicine demonstrate the promise in regenerating cardiac tissue using engineered patches made up of a mixture of fibrin and mesenchymal stem cells (MSCs) derived from human umbilical cord blood.